New York Apparently Followed Illinois’ LEAD, Here, on Vytorin®. . . .

Although I noted the State of New York’s change to Vytorin®‘s status yesterday (having given New York too-much fanfare, perhaps), apparently as early as July 1, 2008, Illinois Medicaid and Illinois Cares Rx Plus had transferred Vytorin® to “non-preferred” status (see page 10 of this July 1, 2008 PDF file):

Preferred Drug List
Illinois Medicaid and Illinois Cares Rx Plus
July 1, 2008
Changes are highlighted in blue
and marked with an asterisk (*)

NON-PREFERRED:

Lipotropics – Statins & Combinations — Vytorin®*. . . .

[All with a very sincere Hat Tip, to the post-midnight anonymous commenter in my comments box, to the New York post, of yesterday.] I’ll likely devise some graphical form of a running state-by-state tally, in the left-margin, starting tomorrow around lunch-time — after I’ve surveyed some of the other, larger, commercial states.]

One response to “New York Apparently Followed Illinois’ LEAD, Here, on Vytorin®. . . .

  1. This isn’t good:

    LONDON (MarketWatch) — Merrill Lynch cut its rating on Schering-Plough (SGP:
    17.45, -1.03, -5.6%) to underperform from neutral and lowered its price target to $18 from $22, saying it expects the efficacy and safety controversies around Vytorin/Zetia to continue. In addition, the broker told clients that the drugmaker has the greatest currency risk of U.S. peers.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s